AxFlow AB ställer ut på Euro Expo i Gällivare 30-31 augusti 2023

Vi kommer att vara där och ser fram emot att prata pumpar för just din applikation.

100 years of Festo

The spirit of invention is deeply rooted in our corporate culture. Since our foundation, we have been setting benchmarks by developing innovative solutions that...

Gruvindustrins utmaning | AxFlow AB

Tailings – från slam till pasta

ABEL nu i vårt sortiment | AxFlow AB

Pumpar för extrema förhållanden.

”We need compatibility“

Penilla Gunther, founder of Fokus Patient and chair of the European Patient Safety Foundation, hopes that the forthcoming life science strategy will focus on ef...

Amorphous materials take centre stage when Orexo develops new formulations

Swift resolution but with maintained stability. Orexo’s new drug delivery platform tackles the problem of amorphous materials. “Our technology has the positive ...

The first vaccine derived from cowpox

The British rural doctor could not forget the words of the peasant girl. Could that really be true? A couple of decades later, on 14 May 1796, he performed the ...

Valves with piezo technology

Efficient control and regulation of gases in medical technology

3 fördelar med kompakta ventilterminaler från Aventics

Från vår tillverkare Aventics hittar du kompakta ventilterminaler i plast vilket gör sig bra inom automationsindustrin.

ZEISS Lightfield 4D for instant volumetric high-speed imaging

Capturing physiological and neuronal processes in 3D.

Astra Zeneca faces potential multimillion-dollar fines in China

Astra Zeneca could be forced to pay up up to $8 million in fines for allegedly unpaid import duties in China, as the company seeks to rebuild trust following ea...

New Horizons in Biologics & Bioprocessing incl. Advanced Therapies: Stockholm (2026)

Samuel Lagercrantz: ”Will the Swedish life science strategy be updated with precision?”

What will the Swedish government focus on in the life science strategy that is being updated? And what should be prioritized in the strategy? Life Science Swede...

Investigations against AstraZeneca: ”Chinese interests may be behind them”

Why are there several investigations against AstraZeneca employees in China right now? Life Science Sweden continues to seek answers.

“Conducting research at universities is becoming more and more like working at a research hotel”

The government wants Swedish research to focus on excellence and innovation, but can the two be combined? Life Science Sweden talks to Anna Falk, a professor at...

Roche’s Genentech terminates licencing deal with Norwegian biotech

Genentech is ending a license collaboration with Norwegian biotech Nykode Therapeutics regarding a clinical stage cancer vaccine program.

Success for Genmab's antibody-drug conjugate

The Danish company Genmab has received Japanese approval for its treatment for advanced or recurrent cervical cancer.

One last chance to register for the premier metrology event in 2024

ZEISS QUALITY INNOVATION SUMMIT.

A green nursery for biotech rooted in the Scanian soil

Red Glead has established itself as one of Lund’s largest companies in pharmaceutical development. Life Science Sweden went to Skåne and met two of the founders...

Joy at Egetis after positive CHMP opinion – ”The single most important milestone”

Stockholm-based Egetis Therapeutics has received a positive CHMP opinion for Emcitate, which could become the first approved treatment for the rare disease MCT8 deficiency."

Achieve Efficient, Fast Targeting of Your Sample

Step into the future of imaging technology with VersaXRM 730.

Automatisering spar 15 heltidsanställda hos Otto Olsen

När man bestämt sig för att kunna erbjuda marknadens största sortiment av industriprodukter och dessutom ha snabba leveranser och service i världsklass gäller d...

AstraZeneca to use American AI platform for cancer trials

In a collaboration AstraZeneca will use an AI model from Israeli-American biotech Immunai to streamline its clinical trials in cancer.

“Everyone is screaming for talent”

Attracting talent is one of the life science industry’s major future challenges, which was one of the conclusions of the panel discussion that ended the New Hor...